Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

Shares of yet an­oth­er NASH hope­ful are rock­et­ing north this morn­ing, with Tel Aviv-based Galmed post­ing news on its Phase IIb fat­ty liv­er dis­ease drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.